Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bimekizumab Delivery Devices in Healthy Volunteers
NCT03707717Phase 1Completed
- Sponsor
- UCB
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of bimekizumab in plaque psoriasis (3 arms), sponsored by UCB. Primary endpoints: Maximum observed plasma drug concentration at Day 140, Area under the plasma concentration-time curve from time zero to last quantifiable concentration at Day 140 and 3 more. Started Oct 2018; status: completed.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03707717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707717.